Kintor Pharmaceutical is dedicated to addressing significant unmet medical needs in dermatology and oncology, particularly focusing on androgen receptor-related diseases such as alopecia, acne, and various cancers. The company has developed a diverse product pipeline that includes small-molecule drugs like AR degraders, mTOR inhibitors, and Hedgehog inhibitors, as well as innovative biologics, notably an ALK-1 antibody aimed at treating multiple cancers. Kintor's commitment to research and development is evident in its globally integrated R&D platform, which leverages the expertise of leading scientists and researchers from both domestic and international pharmaceutical backgrounds.

In addition to its robust R&D efforts, Kintor has established a modern GMP-certified manufacturing base in Suzhou, designed to meet international standards and capable of producing up to 4 million tablets annually. This facility supports the company's goal of efficiently launching its innovative drugs into the market. Kintor is also focused on creating combination therapies to enhance treatment efficacy for conditions like prostate and liver cancers, while actively exploring business development opportunities with global pharmaceutical partners to expand its reach and impact in the healthcare sector.

China

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor and tumor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancers, alopecia and acne. 

Kintor Pharmaceutical

Company Details